2025-06-13-花旗集团-藏寿司（KRUS）_赛尔达克斯治疗公司（CLDX）_中小盘观点_10页_265kb

Summary

Celldex Therapeutics (CLDX.O):

• The Phase 2 study of barzolvolimab in chronic spontaneous urticaria (CSU) showed sustained response rates of 41% (in the 150mg q4w cohort) at week 76, surpassing the clinical meaningful threshold of 12-15%.
• Key safety concerns (neutropenia, hair/skin color changes) were mostly resolved upon drug discontinuation, alleviating safety concerns. The drug is positioned as a potential "last-line" treatment for refractory CSU patients, with premium pricing potential.
• Target Price: $56.00, Recommendation: Buy/High Risk.

Kura Sushi (KRUS.O):

• The upcoming Q3 report is expected to highlight progress on sales drivers, particularly the rollout of reservations and incremental IP collaborations.
• Unit growth is on track for FY25, and future pipeline should ease cannibalization pressures.
• Performance indicators showed mixed results but may reflect early reservation traction, potentially improving customer visits and satisfaction.

Schrodinger Inc (SDGR.O):

• SGR-1505 (MALT1 inhibitor) achieved an overall response rate of 22% in Phase 1 trials for recurrent B-cell malignancies, with a safe profile.
• The company plans to explore combination therapies with BTKi/BCL2i in future Phase 2 studies.
• Target Price: $39.00, Recommendation: Buy/High Risk.

Retail Insights:

• Retail research highlights trends and leverage ratios, aiming to guide investors on key metrics for retailers like KSS, GAP, AEO, and others.
• Commentary focuses on resilience post-holiday season and factors influencing sales and foot traffic.

Weekly REIT & Lodging Strategy:

• Provides a brief review of REIT performance and market dynamics for hotel stocks.
• Citi analysts address common investor questions related to REITs and lodging strategies ahead of economic shifts.

Performance Indices (YTD Data):

• REIT indices (Equity REIT, Model Portfolio) showed positive performance (3.0%–4.5%) but lagged broader indices like S&P 500 (9.1%).
• S&P 500 Total Return (15.0%) and Nasdaq (13.4%) were among the strongest performers, while sectors like Utilities and S&P 400 REITs underperformed.

Key Takeaways:

• Biotech firms (CLDX, SDGR) showed promising clinical updates, supporting potential premium valuations.
• Retailers will benefit from ongoing reservation rollouts and incremental collaborations.
• REIT and lodging sectors are under review for REIT-specific catalysts, with mixed performance.
• Cross-asset opportunities exist, with tech-heavy sectors outperforming traditional indices.